177Lu-TLX591 + Enzalutamide + Abiraterone + Docetaxel
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer
Trial Timeline
Jul 26, 2024 → Dec 1, 2030
NCT ID
NCT06520345About 177Lu-TLX591 + Enzalutamide + Abiraterone + Docetaxel
177Lu-TLX591 + Enzalutamide + Abiraterone + Docetaxel is a phase 3 stage product being developed by Telix Pharmaceuticals for Metastatic Castration-resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06520345. Target conditions include Metastatic Castration-resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06520345 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Castration-resistant Prostate Cancer